


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-212)	CARBETOCIN
PRONUNCIATION	kar" be toe' sin
THERAPEUTIC CLAIM	Treatment of Prader-Willi syndrome; Prevention of post-partum hemorrhage due to uterine atony
CHEMICAL NAMES	

1. Glycinamide, *N*-(4-mercapto-1-oxobutyl)-*O*-methyl-L-tyrosyl-L-isoleucyl-L-glutaminy-L-asparaginy-L-cysteinyl-L-prolyl-L-leucyl-, cyclic (1→5)-thioether (Source: CAS)
2. *O*-methyl-*N*-(4-sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminy-L-asparaginy-L-cysteinyl-L-prolyl-L-leucyl-glycinamide cyclic (1→5)-thioether

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₄₅ H ₆₉ N ₁₁ O ₁₂ S
MOLECULAR WEIGHT	988.16
TRADEMARK	Duratocin; Duratocin long acting; Pabal
SPONSOR	Levo Therapeutics
CODE DESIGNATIONS	LV-101; FE 992097
<u>CAS</u> REGISTRY NUMBER	37025-55-1
UNII	88TWF8015Y
WHO NUMBER	5014

gbk